← Back to Search

Tyrosine Kinase Inhibitor

Cabozantinib + Nivolumab + Ipilimumab for Kidney Cancer

Phase 2
Recruiting
Led By Bradley McGregor, MD
Research Sponsored by Bradley A. McGregor, MD
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Age ≥ 18 years
ECOG performance status ≤1
Must not have
Bleeding diathesis, or significant coagulopathy in the absence of therapeutic anticoagulation
Prior allogenic stem cell or solid organ transplant
Timeline
Screening 3 weeks
Treatment Varies
Follow Up defined as the percentage of patients with partial (pr) or complete response (cr) as best overall response according to recist 1.1 by investigator assessment up to 21 months
Awards & highlights
No Placebo-Only Group

Summary

This trial is testing a combination of three drugs to see if they can slow down advanced kidney cancer that has spread. The drugs work by stopping cancer growth and helping the immune system attack the cancer. About 40 people will participate in this study.

Who is the study for?
Adults with advanced or metastatic non-clear cell renal cell carcinoma (nccRCC) who haven't had certain previous treatments can join. They must be able to provide a fresh tumor biopsy, use contraception, and have normal organ/marrow function. Excluded are those with specific heart diseases, autoimmune conditions, lung fibrosis, bleeding disorders without therapeutic anticoagulation, severe infections or on strong CYP3A4 inhibitors/inducers.
What is being tested?
The trial is testing the combination of Cabozantinib with immunotherapy drugs Nivolumab and Ipilimumab for effectiveness in slowing kidney cancer growth. Participants will receive all three medications to see if they work better together than current standard treatments.
What are the potential side effects?
Possible side effects include liver problems, diarrhea, fatigue, skin rash and itching. There may also be risks of immune-related issues like inflammation in organs such as lungs or intestines and potential hormonal gland problems.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am 18 years old or older.
Select...
I am fully active and can carry on all pre-disease activities without restriction.
Select...
My kidney cancer cannot be removed by surgery and has spread.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have a bleeding disorder not caused by blood thinners.
Select...
I have had a previous transplant of an organ or stem cells from a donor.
Select...
I am not taking any strong drugs that affect liver enzymes.
Select...
I cannot receive medications through an IV.
Select...
I have a history of specific lung conditions or signs of lung inflammation on a recent chest CT.
Select...
I have been treated with cabozantinib before.
Select...
I have been treated with CD137 agonists and immune checkpoint inhibitors before.
Select...
I have a history of certain infectious diseases.
Select...
I have a condition that prevents my body from absorbing nutrients properly.
Select...
I have serious heart problems.
Select...
I haven't taken any immunosuppressive drugs in the last 2 weeks.
Select...
I cannot swallow pills.
Select...
I have a serious stomach or intestine condition that could lead to bleeding or a tear.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~defined as the percentage of patients with partial (pr) or complete response (cr) as best overall response according to recist 1.1 by investigator assessment up to 21 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and defined as the percentage of patients with partial (pr) or complete response (cr) as best overall response according to recist 1.1 by investigator assessment up to 21 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Overall Response Rate
Secondary study objectives
"Number of Participants with TreatmentRelated Adverse Events as Assessed by CTCAE version 5.
Duration of response (DOR)
Objective response rate (ORR)
+4 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: CabozantinibExperimental Treatment3 Interventions
Eligible patients will be enrolled and receive treatment with * Cycle 1-4 (cycles of 21 days) * Cabozantinib predetermined protocol dosage po daily * Nivolumab predetermined protocol dosage via IV every 3 weeks * Ipilimumab predetermined protocol dosage via IV every 3 weeks * After the first four cycles of therapy, * Cabozantinib determined protocol dosage po daily * Nivolumab predetermined protocol dosage via IV every 3 weeks (cycles of 28 days)
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Cabozantinib
2020
Completed Phase 2
~1760
Ipilimumab
2014
Completed Phase 3
~3140
Nivolumab
2014
Completed Phase 3
~5220

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
The most common treatments for Renal Cell Carcinoma (RCC) include Tyrosine Kinase Inhibitors (TKIs) and Immune Checkpoint Inhibitors (ICIs). TKIs, like Cabozantinib, inhibit enzymes that promote cancer cell growth and angiogenesis, thereby slowing tumor progression. ICIs, such as Nivolumab and Ipilimumab, enhance the immune system's ability to target and destroy cancer cells by blocking inhibitory proteins on immune cells. This dual approach is significant for RCC patients as it combines direct inhibition of tumor growth with an enhanced immune response, offering a comprehensive strategy to manage advanced or metastatic RCC.
Results of a multicenter, phase 2 study of nivolumab and ipilimumab for patients with advanced rare genitourinary malignancies.Immunotherapy in kidney cancer: the past, present, and future.Nivolumab for the treatment of cancer.

Find a Location

Who is running the clinical trial?

Bradley A. McGregor, MDLead Sponsor
2 Previous Clinical Trials
39 Total Patients Enrolled
Bristol-Myers SquibbIndustry Sponsor
2,680 Previous Clinical Trials
4,125,022 Total Patients Enrolled
ExelixisIndustry Sponsor
120 Previous Clinical Trials
19,859 Total Patients Enrolled

Media Library

Cabozantinib (Tyrosine Kinase Inhibitor) Clinical Trial Eligibility Overview. Trial Name: NCT04413123 — Phase 2
Renal Cell Carcinoma Research Study Groups: Cabozantinib
Renal Cell Carcinoma Clinical Trial 2023: Cabozantinib Highlights & Side Effects. Trial Name: NCT04413123 — Phase 2
Cabozantinib (Tyrosine Kinase Inhibitor) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04413123 — Phase 2
~2 spots leftby Dec 2024